Correspondence on "Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI)" by Ferreira et al
- PMID: 34127825
- DOI: 10.1038/s41436-021-01228-4
Correspondence on "Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI)" by Ferreira et al
Comment in
-
Response to Stern et al.Genet Med. 2021 Oct;23(10):2008. doi: 10.1038/s41436-021-01229-3. Epub 2021 Jun 16. Genet Med. 2021. PMID: 34135486 Free PMC article. No abstract available.
Comment on
-
Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI).Genet Med. 2021 Feb;23(2):396-407. doi: 10.1038/s41436-020-00983-0. Epub 2020 Oct 2. Genet Med. 2021. PMID: 33005041 Free PMC article.
References
-
- Ferreira, C. R. et al. Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI). Genet. Med. 23, 396–407 (2021). - DOI
-
- Carpenter, T. O. et al. Burosumab therapy in children with X-linked hypophosphatemia. N. Engl. J. Med. 378, 1987–1998 (2018). - DOI
-
- Boyce, A. M., Gafni, R. I. & Ferreira, C. R. Generalized arterial calcification of infancy: new insights, controversies, and approach to management. Curr. Osteoporos. Rep. 18, 232–241 (2020). - DOI
-
- Rutsch, F. et al. Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ. Cardiovasc. Genet. 1, 133–140 (2008). - DOI
-
- Imel, E. A. et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 393, 2416–2427 (2019). - DOI
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
